AU2006224796A1 - Anti-inflammatory compounds - Google Patents

Anti-inflammatory compounds Download PDF

Info

Publication number
AU2006224796A1
AU2006224796A1 AU2006224796A AU2006224796A AU2006224796A1 AU 2006224796 A1 AU2006224796 A1 AU 2006224796A1 AU 2006224796 A AU2006224796 A AU 2006224796A AU 2006224796 A AU2006224796 A AU 2006224796A AU 2006224796 A1 AU2006224796 A1 AU 2006224796A1
Authority
AU
Australia
Prior art keywords
substituted
nmr
formula
compound
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006224796A
Other languages
English (en)
Inventor
Josef Gottfried Meingassner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2006224796A1 publication Critical patent/AU2006224796A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AU2006224796A 2005-03-17 2006-03-15 Anti-inflammatory compounds Abandoned AU2006224796A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0505541.3 2005-03-17
GBGB0505541.3A GB0505541D0 (en) 2005-03-17 2005-03-17 Organic compounds
PCT/EP2006/002382 WO2006097292A1 (en) 2005-03-17 2006-03-15 Anti-inflammatory compounds

Publications (1)

Publication Number Publication Date
AU2006224796A1 true AU2006224796A1 (en) 2006-09-21

Family

ID=34531452

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006224796A Abandoned AU2006224796A1 (en) 2005-03-17 2006-03-15 Anti-inflammatory compounds

Country Status (12)

Country Link
US (1) US20090227620A1 (cg-RX-API-DMAC7.html)
EP (1) EP1861098A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008533079A (cg-RX-API-DMAC7.html)
KR (1) KR20070113226A (cg-RX-API-DMAC7.html)
CN (1) CN101137375A (cg-RX-API-DMAC7.html)
AU (1) AU2006224796A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0607795A2 (cg-RX-API-DMAC7.html)
CA (1) CA2599470A1 (cg-RX-API-DMAC7.html)
GB (1) GB0505541D0 (cg-RX-API-DMAC7.html)
MX (1) MX2007011320A (cg-RX-API-DMAC7.html)
RU (1) RU2007138263A (cg-RX-API-DMAC7.html)
WO (1) WO2006097292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200900960A1 (ru) * 2007-01-31 2010-02-26 Новартис Аг Производные пиперидинацетамида для лечения воспалительных или аллергических заболеваний
JP5543920B2 (ja) 2007-09-17 2014-07-09 プレグレム エスアー 閉経前の女性におけるエストロゲン依存症状の治療
TW200936136A (en) * 2008-01-28 2009-09-01 Sanofi Aventis Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
MX2012014958A (es) 2010-06-15 2013-02-12 Bayer Ip Gmbh Derivados de diamida antranilica.
CN102657642B (zh) * 2012-04-24 2014-01-15 广东省农业科学院兽医研究所 Irosustat在制备抗柔嫩艾美耳球虫药物中的应用
CA2874621A1 (en) 2012-05-22 2013-11-28 Genentech, Inc. N-substituted benzamides and their use in the treatment of pain
CN107417601A (zh) * 2017-04-06 2017-12-01 成都弥贝生物科技有限公司 具有抗菌活性的取代2‑酰胺磺酰基‑4,6‑芳基吡啶
KR102458689B1 (ko) * 2020-07-08 2022-10-25 원광대학교산학협력단 피페리딘 화합물 및 이의 제조 방법
WO2025079965A1 (ko) * 2023-10-10 2025-04-17 주식회사 넥시온바이오텍 치주 질환의 예방 또는 치료용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9807779D0 (en) * 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
GB0020498D0 (en) * 2000-08-18 2000-10-11 Sterix Ltd Compound
US6986938B2 (en) * 2001-10-03 2006-01-17 A & A Manufacturing Co., Inc. Bellows with molded panels
AR037097A1 (es) * 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
PE20040167A1 (es) * 2002-03-28 2004-05-26 Novartis Ag Amidas del acido sulfamico
AR041952A1 (es) * 2002-11-14 2005-06-01 Novartis Ag N-sulfonilaminotiazol

Also Published As

Publication number Publication date
RU2007138263A (ru) 2009-04-27
CN101137375A (zh) 2008-03-05
JP2008533079A (ja) 2008-08-21
MX2007011320A (es) 2007-11-08
WO2006097292A1 (en) 2006-09-21
CA2599470A1 (en) 2006-09-21
US20090227620A1 (en) 2009-09-10
KR20070113226A (ko) 2007-11-28
GB0505541D0 (en) 2005-04-27
BRPI0607795A2 (pt) 2009-06-13
EP1861098A1 (en) 2007-12-05

Similar Documents

Publication Publication Date Title
AU2002357333B2 (en) Alpha-(N-sulphonamido)acetamide derivatives as Beta-amyloid inhibitors
RU2746188C2 (ru) Ингибиторы ионного канала, фармацевтические составы и применение
MXPA06014574A (es) Piperidinas n-sustituidas y su uso como farmaceuticos.
AU2007210018A1 (en) Amido compounds and their use as pharmaceuticals
AU2005267331A1 (en) Amido compounds and their use as pharmaceuticals
AU2002350490B2 (en) Acylsulfonamides as inhibitors of steroid sulfatase
AU2002350490A1 (en) Acylsulfonamides as inhibitors of steroid sulfatase
AU2006224796A1 (en) Anti-inflammatory compounds
AU2025201400A1 (en) Glycyrrhetinic acid derivatives for treating hyperkalemia
AU2003226732B2 (en) Piperazinyl- or piperidinylamine-sulfamic acid amides as inhibitors of steroid sulfatase
AU2006224797B2 (en) Combination of a steroid sulfatase inhibitor and an ascomycin
TWI449700B (zh) 作為組織胺ｈ３受體拮抗劑之三亞甲亞胺類
WO2020154431A1 (en) Inhibitors of spinster homolog 2 (spns2) for use in therapy

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted